Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

BACKGROUND: A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Joachim, Agricola, Bauer, Asli, Joseph, Sarah, Geldmacher, Christof, Munseri, Patricia J., Aboud, Said, Missanga, Marco, Mann, Philipp, Wahren, Britta, Ferrari, Guido, Polonis, Victoria R., Robb, Merlin L., Weber, Jonathan, Tatoud, Roger, Maboko, Leonard, Hoelscher, Michael, Lyamuya, Eligius F., Biberfeld, Gunnel, Sandström, Eric, Kroidl, Arne, Bakari, Muhammad, Nilsson, Charlotta, McCormack, Sheena
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4871571/
https://ncbi.nlm.nih.gov/pubmed/27192151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados